otc:caps
|
1448132
|
Apr 14th, 2024 12:00AM
|
Capstone Therapeutics
|
144
|
8.00
|
Open
|
|
Apr 14th, 2024 01:58AM
|
Apr 14th, 2024 01:58AM
|
Capstone Therapeutics (OTCQB: CAPS) is a clinical stage biotechnology company developing a family of new peptide drugs to serve cardiovascular patients with high cholesterol and triglyceride levels otherwise unaddressable through standard therapy. Capstone holds an FDA Orphan drug designation for its lead molecule, AEM-28, for Homozygous Familial Hypercholesterolemia (HoFH) and may also target indications in acute coronary syndrome, peripheral artery disease and type 2 diabetes.
|
Open
|
|
Open
|
|
|
|
|
|
|
Capstone Therapeutics
|
|
|
otc:caps
|
1448132
|
Apr 13th, 2024 12:00AM
|
Capstone Therapeutics
|
144
|
8.00
|
Open
|
|
Apr 13th, 2024 01:19AM
|
Apr 13th, 2024 01:38PM
|
Capstone Therapeutics (OTCQB: CAPS) is a clinical stage biotechnology company developing a family of new peptide drugs to serve cardiovascular patients with high cholesterol and triglyceride levels otherwise unaddressable through standard therapy. Capstone holds an FDA Orphan drug designation for its lead molecule, AEM-28, for Homozygous Familial Hypercholesterolemia (HoFH) and may also target indications in acute coronary syndrome, peripheral artery disease and type 2 diabetes.
|
Open
|
|
Open
|
|
|
|
|
|
|
Capstone Therapeutics
|
|
|
otc:caps
|
1448132
|
Apr 12th, 2024 12:00AM
|
Capstone Therapeutics
|
144
|
8.00
|
Open
|
|
Apr 12th, 2024 01:30AM
|
Apr 12th, 2024 10:39AM
|
Capstone Therapeutics (OTCQB: CAPS) is a clinical stage biotechnology company developing a family of new peptide drugs to serve cardiovascular patients with high cholesterol and triglyceride levels otherwise unaddressable through standard therapy. Capstone holds an FDA Orphan drug designation for its lead molecule, AEM-28, for Homozygous Familial Hypercholesterolemia (HoFH) and may also target indications in acute coronary syndrome, peripheral artery disease and type 2 diabetes.
|
Open
|
|
Open
|
|
|
|
|
|
|
Capstone Therapeutics
|
|
|
otc:caps
|
1448132
|
Apr 11th, 2024 12:00AM
|
Capstone Therapeutics
|
144
|
8.00
|
Open
|
|
Apr 11th, 2024 03:41AM
|
Apr 11th, 2024 01:22PM
|
Capstone Therapeutics (OTCQB: CAPS) is a clinical stage biotechnology company developing a family of new peptide drugs to serve cardiovascular patients with high cholesterol and triglyceride levels otherwise unaddressable through standard therapy. Capstone holds an FDA Orphan drug designation for its lead molecule, AEM-28, for Homozygous Familial Hypercholesterolemia (HoFH) and may also target indications in acute coronary syndrome, peripheral artery disease and type 2 diabetes.
|
Open
|
|
Open
|
|
|
|
|
|
|
Capstone Therapeutics
|
|
|
otc:caps
|
1448132
|
Apr 10th, 2024 12:00AM
|
Capstone Therapeutics
|
144
|
8.00
|
Open
|
|
Apr 10th, 2024 01:26AM
|
Apr 10th, 2024 07:26PM
|
Capstone Therapeutics (OTCQB: CAPS) is a clinical stage biotechnology company developing a family of new peptide drugs to serve cardiovascular patients with high cholesterol and triglyceride levels otherwise unaddressable through standard therapy. Capstone holds an FDA Orphan drug designation for its lead molecule, AEM-28, for Homozygous Familial Hypercholesterolemia (HoFH) and may also target indications in acute coronary syndrome, peripheral artery disease and type 2 diabetes.
|
Open
|
|
Open
|
|
|
|
|
|
|
Capstone Therapeutics
|
|
|
otc:caps
|
1448132
|
Apr 9th, 2024 12:00AM
|
Capstone Therapeutics
|
144
|
8.00
|
Open
|
|
Apr 9th, 2024 01:54AM
|
Apr 9th, 2024 12:09PM
|
Capstone Therapeutics (OTCQB: CAPS) is a clinical stage biotechnology company developing a family of new peptide drugs to serve cardiovascular patients with high cholesterol and triglyceride levels otherwise unaddressable through standard therapy. Capstone holds an FDA Orphan drug designation for its lead molecule, AEM-28, for Homozygous Familial Hypercholesterolemia (HoFH) and may also target indications in acute coronary syndrome, peripheral artery disease and type 2 diabetes.
|
Open
|
|
Open
|
|
|
|
|
|
|
Capstone Therapeutics
|
|
|
otc:caps
|
1448132
|
Apr 8th, 2024 12:00AM
|
Capstone Therapeutics
|
144
|
8.00
|
Open
|
|
Apr 8th, 2024 02:31AM
|
Apr 8th, 2024 09:05PM
|
Capstone Therapeutics (OTCQB: CAPS) is a clinical stage biotechnology company developing a family of new peptide drugs to serve cardiovascular patients with high cholesterol and triglyceride levels otherwise unaddressable through standard therapy. Capstone holds an FDA Orphan drug designation for its lead molecule, AEM-28, for Homozygous Familial Hypercholesterolemia (HoFH) and may also target indications in acute coronary syndrome, peripheral artery disease and type 2 diabetes.
|
Open
|
|
Open
|
|
|
|
|
|
|
Capstone Therapeutics
|
|
|
otc:caps
|
1448132
|
Apr 7th, 2024 12:00AM
|
Capstone Therapeutics
|
144
|
8.00
|
Open
|
|
Apr 7th, 2024 02:08AM
|
Apr 7th, 2024 02:08AM
|
Capstone Therapeutics (OTCQB: CAPS) is a clinical stage biotechnology company developing a family of new peptide drugs to serve cardiovascular patients with high cholesterol and triglyceride levels otherwise unaddressable through standard therapy. Capstone holds an FDA Orphan drug designation for its lead molecule, AEM-28, for Homozygous Familial Hypercholesterolemia (HoFH) and may also target indications in acute coronary syndrome, peripheral artery disease and type 2 diabetes.
|
Open
|
|
Open
|
|
|
|
|
|
|
Capstone Therapeutics
|
|
|
otc:caps
|
1448132
|
Apr 6th, 2024 12:00AM
|
Capstone Therapeutics
|
144
|
8.00
|
Open
|
|
Apr 6th, 2024 01:45AM
|
Apr 6th, 2024 01:45AM
|
Capstone Therapeutics (OTCQB: CAPS) is a clinical stage biotechnology company developing a family of new peptide drugs to serve cardiovascular patients with high cholesterol and triglyceride levels otherwise unaddressable through standard therapy. Capstone holds an FDA Orphan drug designation for its lead molecule, AEM-28, for Homozygous Familial Hypercholesterolemia (HoFH) and may also target indications in acute coronary syndrome, peripheral artery disease and type 2 diabetes.
|
Open
|
|
Open
|
|
|
|
|
|
|
Capstone Therapeutics
|
|
|
otc:caps
|
1448132
|
Apr 5th, 2024 12:00AM
|
Capstone Therapeutics
|
144
|
8.00
|
Open
|
|
Apr 5th, 2024 04:28AM
|
Apr 5th, 2024 04:28AM
|
Capstone Therapeutics (OTCQB: CAPS) is a clinical stage biotechnology company developing a family of new peptide drugs to serve cardiovascular patients with high cholesterol and triglyceride levels otherwise unaddressable through standard therapy. Capstone holds an FDA Orphan drug designation for its lead molecule, AEM-28, for Homozygous Familial Hypercholesterolemia (HoFH) and may also target indications in acute coronary syndrome, peripheral artery disease and type 2 diabetes.
|
Open
|
|
Open
|
|
|
|
|
|
|
Capstone Therapeutics
|
|
|